Takeda’s $5.2B Ariad Deal Yields Label Expansion for Iclusig in Rare Leukemia

1. Takeda's cancer drug Iclusig has received accelerated approval from the FDA in combination with chemotherapy, as reported on March 19, 2024.
2. This label expansion is a result of Takeda's $5.2 billion acquisition of Ariad.
3. The approval is for the treatment of newly diagnosed patients with a rare form of leukemia.
4. The accelerated approval was granted based on the drug's potential to address an unmet medical need.

Please note that the information provided is based on the search results from April 17, 2024, and it reflects the latest news available at that time.